This clinical trial studies a combination treatment for Extensive-stage Small Cell Lung Cancer. The study tests a new treatment approach that combines several medications: BMS-986012 (an experimental antibody), carboplatin, etoposide, and nivolumab. The purpose is to evaluate how safe and effective this combination therapy is compared to standard treatment.
The study involves two different treatment approaches. One group of patients receives all four medications (BMS-986012, carboplatin, etoposide, and nivolumab) for the first part of treatment, followed by continued treatment with BMS-986012 and nivolumab. The other group receives only carboplatin, etoposide, and nivolumab initially, followed by nivolumab alone.
During the study, patients will undergo regular medical examinations and imaging tests such as computed tomography or magnetic resonance imaging to monitor how well the treatment is working. The researchers will track how the cancer responds to treatment and monitor any side effects that may occur. The study will also measure how long patients live without their cancer getting worse and their overall survival time.



Belgium
Greece
Italy
Poland
Romania
Spain
The Netherlands